Company / Cash & Equivalents
Bausch Health Companies Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.3B
FY2025
5-year range
$564.0M / $1.3B
FY2021-FY2025
Trend
+10.8%
vs FY2024
Sector context
#18 of 207
Health Care
What the data says
Among 207 Health Care companies, Bausch Health Companies Inc. is in the top 9% for cash & equivalents. Improved from $564M to $1.3B over the past 2 years.
Based on SEC 10-K filings.
$1.3B in FY2025 with a 5-year CAGR of +12.7%. Top quartile in the Health Care sector.
Improved from $564M to $1.3B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +31.0%
- 5-Year CAGR
- +12.7%
- 10-Year CAGR
- -
Sector benchmark
Top 9% in Health CareTop 9% of 207This company $1.3B Sector average $669.5M
▼
+95.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +12.7%, indicating consistent growth.
- In FY2025, cash & equivalents increased 10.8% year-over-year.
- Ranks #18 out of 207 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.3B | +10.8% |
| FY2024 | $1.2B | +109.4% |
| FY2023 | $564.0M | -3.1% |
| FY2022 | $582.0M | +0.0% |
| FY2021 | $582.0M | -19.3% |
| FY2020 | $721.0M | +0.0% |
| FY2019 | $721.0M | +0.1% |
| FY2018 | $720.0M | +0.0% |
| FY2017 | $720.0M | +32.8% |
| FY2016 | $542.0M | -9.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026